Literature DB >> 17850537

Neuroactive properties of reproductive steroids.

Andrew G Herzog1.   

Abstract

Migraine is 3 times more common in postpubertal women than in men. Migraine is frequently exacerbated perimenstrually and commonly occurs exclusively at that time. It is often benefited by pregnancy and menopause. Estrogen withdrawal has been implicated as a mechanism for triggering migraines. The mechanism, however, is not well understood. Reproductive steroids have neuroactive properties that can modulate neuronal morphology and physiology. Increasing evidence suggests that circulating reproductive steroid levels regulate the balance of neuroexcitatory and neuroinhibitory activities in some brain regions by influencing synaptic plasticity. Estrogen has neuroexcitatory, whereas progesterone has neuroinhibitory, effects in most preclinical and clinical models. Several neurotransmitter systems that are implicated in migraine vary with reproductive steroid levels during the reproductive cycle. Estrogen stabilization may provide effective treatment in susceptible women, especially for catamenially exacerbated migraine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17850537     DOI: 10.1111/j.1526-4610.2007.00817.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  7 in total

Review 1.  [Gender aspects in anesthesia : modified approach in research and treatment?].

Authors:  M Schopper; P I Bäumler; J Fleckenstein; D Irnich
Journal:  Anaesthesist       Date:  2012-04       Impact factor: 1.041

Review 2.  Hormonal contraception and migraine: clinical considerations.

Authors:  Stephanie S Faubion; Petra M Casey; Lynne T Shuster
Journal:  Curr Pain Headache Rep       Date:  2012-10

Review 3.  [Gender differences in acute and chronic pain conditions. Implications for diagnosis and therapy].

Authors:  M Schopper; J Fleckenstein; D Irnich
Journal:  Schmerz       Date:  2013-09       Impact factor: 1.107

4.  Hormonal manipulation strategies in the management of menstrual migraine and other hormonally related headaches.

Authors:  Lynne T Shuster; Stephanie S Faubion; Richa Sood; Petra M Casey
Journal:  Curr Neurol Neurosci Rep       Date:  2011-04       Impact factor: 5.081

Review 5.  Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics.

Authors:  Robin Ortiz; Henning Ulrich; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-11-07       Impact factor: 5.067

6.  The second to fourth digit ratio (2D:4D): a risk factor of migraine and tension-type headache.

Authors:  Wei Xie; Mianwang He; Ruozhuo Liu; Zhao Dong; Jingdan Xie; Dan Wang; Shengyuan Yu
Journal:  J Headache Pain       Date:  2015-02-11       Impact factor: 7.277

7.  Diagnosis and management of catamenial seizures: a review.

Authors:  Alberto Verrotti; Claudia D'Egidio; Sergio Agostinelli; Carla Verrotti; Piero Pavone
Journal:  Int J Womens Health       Date:  2012-09-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.